AVDL stock trades at $21.64 after a quiet market close on 05 Mar 2026, with Avadel Pharmaceuticals plc (AVDL) preparing to report quarterly results on 09 Mar 2026. The narrow intraday range masks heavy volume interest today — 35,016,239.00 shares traded versus an average of 2,415,222.00. Investors will watch revenue cadence, FT218 development updates, and margin commentary. This earnings report is the most likely near-term catalyst to move price and reset expectations for the drug maker listed on NASDAQ in the United States (USD).

AVDL stock: Earnings setup and key dates

Avadel Pharmaceuticals (AVDL) will announce results on 09 Mar 2026 and market focus is on trial progress and commercial timing for FT218. The company has EPS -0.02 and a trailing PE shown as -1082.00, reflecting negative earnings. Management commentary on guidance and cash runway will determine whether today’s price $21.64 re-rates higher or falls toward the year low $6.38.

AVDL stock: Recent price, volume and momentum signals

AVDL closed at $21.64 with volume 35,016,239.00, a relative volume of 14.50 pointing to outsized trading interest. Technicals show an RSI of 62.60 and ADX 64.05, indicating strength; Bollinger bands sit at 21.67/21.56/21.45. Short-term momentum supports continuation but high MFI at 89.78 signals short-term overbought risk into earnings.

AVDL stock: Fundamentals and valuation snapshot

The market value stands at 2,123,997,811.00 with price/50-day average 21.50 and price/200-day average 15.49, highlighting recent outperformance. Key metrics include current ratio 2.76, debt/equity 0.38, price/sales 8.55, and free cash flow yield 0.02, underscoring biotech valuation premium with limited earnings. Investors should weigh strong gross margins against thin net margins and long inventory days.

AVDL stock: Analyst consensus and external context

Broker data shows 2 Buy, 4 Hold with a consensus score around 3.00, reflecting mixed views ahead of earnings. For peer context see MarketBeat’s competitor list and an industry comparison on Investing.com for relative positioning MarketBeat competitor list and Investing.com comparison. Expect analyst reaction to hinge on FT218 data and cadence for commercialization.

AVDL stock: Meyka AI grade and model forecast

Meyka AI rates AVDL with a score of 71.40 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly level of $32.43 and a yearly level of $18.59 versus the current price $21.64, implying a potential upside to the quarterly path of 49.88% and a yearly downside of -14.11%. Forecasts are model-based projections and not guarantees.

AVDL stock: Risks, price targets and what to watch at earnings

Key risks include trial delays, weaker-than-expected FT218 uptake commentary, and margin pressure. We set price targets at $18.00 (bear), $26.00 (base), and $33.00 (bull), implying -16.82%, +20.15%, and +52.49% from $21.64 respectively. Watch cash commentary, R&D cadence, and any changes to 2026 commercialization timelines.

Final Thoughts

AVDL stock is trading at $21.64 on NASDAQ in the United States (USD) ahead of the 09 Mar 2026 earnings release. The company shows strong gross margins and a solid current ratio but negative EPS and stretched valuation multiples such as price/sales 8.55 and price/book 21.39. Meyka AI’s model offers a split signal: a quarterly project at $32.43 (implying +49.88%) and a yearly project at $18.59 (implying -14.11%). Our price-target bands of $18.00 / $26.00 / $33.00 frame a risk/reward profile that favors event-driven traders ahead of results. For investors focused on fundamentals, monitor guidance and FT218 trial milestones closely. Remember these forecasts and the Meyka AI grade are model outputs and not guarantees; we are not financial advisors. For more company context visit the Meyka page for Avadel at Meyka AVDL page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.